We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Novel Classification System Identifies Prostate Cancer Patients Who May Benefit from Combined Immune and Radiation Therapies

By LabMedica International staff writers
Posted on 22 Dec 2020
Print article
Image: Micrograph showing a prostate cancer (conventional adenocarcinoma) with perineural invasion (Photo courtesy of Wikimedia Commons)
Image: Micrograph showing a prostate cancer (conventional adenocarcinoma) with perineural invasion (Photo courtesy of Wikimedia Commons)
A novel classification system is expected to aid in the subtyping of aggressive prostate cancers in patients who may benefit from combined immune and radiation therapies.

Prostate cancer is graded from 1 to 5 based on how aggressive it is, with 5 being the most aggressive. Patients with 4/5 grade cancers are at the highest risk of poor outcomes or death from the disease. However, currently there are no immunologic or genomic indicators for determination of the best course of treatment for this group of patients.

Investigators at the Moffitt Cancer Center & Research Institute (Tampa, FL, USA) employed two classifiers – the tumor immune content score (ICS) and the Decipher genomic classifier - to assess whether transcriptomic interactions between the two classifiers could identify the most lethal subsets of grade 4/5 prostate cancers. The ICS was derived from the mean expression of 264 immune cell-specific genes, while the Decipher score was based on 22 RNA biomarkers that predicted the probability that a cancer would spread.

For the current study, the investigators analyzed data from 8,071 prostate cancer patient samples of any disease grade (6,071 prostatectomy and 2,000 treatment naïve) in the Decipher Genomics Resource Information Database (GRID) registry. Each patient sample also received an ICS rating.

The samples were separated into four distinct immuno/genomic subsets based on the results: ICS high/Decipher high, ICS low/Decipher high, ICS high/Decipher low, and ICS low/Decipher low.

Results of the analyses revealed that approximately 25% of all grade 4/5 patient samples were in the ICS high/Decipher high subset. The ICS high/Decipher high subtype was associated with increased sensitivity to radiotherapy. Additionally, the ICS high/Decipher high subtype had a significantly higher risk of distant metastasis as compared with the ICS low/Decipher low subtype.

The creation of these novel immuno/genomic subtypes established a very strong synergistic interaction between ICS and Decipher in identifying grade 4/5 prostate cancer patients who are likely to experience the most lethal outcomes.

"Our results will aid in the subtyping of aggressive prostate cancer patients who may benefit from combined immune-radiotherapy modalities," said first author Dr. Kosj Yamoah, director of cancer disparities research at the Moffitt Cancer Center.

The study was published in the December 7, 2020, online edition of the journal European Urology.

Related Links:
Moffitt Cancer Center & Research Institute

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.